This volume presents results from the tenth anniversary meeting of the British Association for Psychopharmacology. It differs from previous BAP monographs in being a general review of the entire discipline, describing extensive recent progress, and identifying areas where work remains to be done. The papers focus on five major areas: depression and antidepressants, anxiolytics, cognitive disorders (particularly Alzheimer's disease), schizophrenia, and various forms of drug addiction. Topics addressed include the proliferation of new pharmaceutical agents, undesirable side effects, the potential hazards of current emphasis on the dopamine overactivity hypothesis, and the impact of CNS drugs. This will be an important resource for clinicians in neurology, psychiatry, and pharmacology; pharmacologists; and students and researchers in psychology, especially neuropsychology and behavioral pharmacology.